Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

Gabrielson Andrew; Tesfaye Anteneh A.; Marshall John L.; Pishvaian Michael J.; Smaglo Brandon; Jha Reena; Dorsch-Vogel Karen; Wang Hongkun; He Aiwu Ruth

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

【24h】

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

机译：替莫唑胺和维利帕利布联合治疗索拉非尼难治性晚期肝细胞癌的II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC).

机译：为了确定替莫唑胺（TMZ）和维立普利布（ABT-888）在晚期索拉非尼难治性肝细胞癌（HCC）患者中的抗肿瘤功效和耐受性。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2015年第5期|共7页
作者
Gabrielson Andrew; Tesfaye Anteneh A.; Marshall John L.; Pishvaian Michael J.; Smaglo Brandon; Jha Reena; Dorsch-Vogel Karen; Wang Hongkun; He Aiwu Ruth;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Refractory; Hepatocellular carcinoma; Temozolomide; Veliparib;

机译：难治性;肝细胞癌;替莫唑胺;Veliparib;

相似文献

外文文献
中文文献
专利

1. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma [J] . Gabrielson Andrew, Tesfaye Anteneh A., Marshall John L., Cancer chemotherapy and pharmacology. . 2015,第5期

机译：替莫唑胺和维利帕利布联合治疗索拉非尼难治性晚期肝细胞癌的II期研究
2. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients [J] . Won Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, Investigational new drugs. . 2018,第6期

机译：第一线组合治疗与索拉非尼蛋白酶，口服HDAC抑制剂，对东亚患者晚期肝细胞癌的索拉非尼治疗，对索拉非尼抑制剂的第一线组合治疗研究
3. Efficacy and safety of sorafenib–gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study [J] . Naeem Naqi, Shaharyar Ahmad, Sohail Murad, Hematology/Oncology and Stem Cell Therapy . 2014,第1期

机译：索拉非尼-吉西他滨联合疗法在晚期肝细胞癌中的疗效和安全性：开放标签的II期可行性研究
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma [D] . YOSHIDA MAIKO, 吉田舞子 2019

机译：质子治疗后血清α甲胎蛋白和维生素K拮抗剂II水平诱导的蛋白的短暂增加不一定表明肝细胞癌的进展
6. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma [O] . Andrew Gabrielson, Anteneh A. Tesfaye, John L. Marshall, -1

机译：替莫唑胺和维利帕利布联合治疗索拉非尼难治性晚期肝细胞癌的II期研究
7. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma [O] . Andrew Gabrielson, Anteneh A. Tesfaye, John L. Marshall, 2015

机译：替莫唑胺和维利帕利布联合治疗索拉非尼难治性晚期肝细胞癌的II期研究

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅